Sekar Kathiresan - 18 Mar 2022 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role: Chief Executive Officer, Director
Signature: /s/ Andrew Ashe, as Attorney-in-Fact for Sekar Kathiresan
Issuer symbol: VERV
Transactions as of: 18 Mar 2022
Net transactions value: +$199,964
Form type: 4
Filing time: 22 Mar 2022, 07:41:17 UTC
Previous filing: 15 Feb 2022
Next filing: 15 Jul 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VERV	Common Stock	Options Exercise	$199,964	+69,674	+17%	$2.87^*	477,525	18 Mar 2022	Direct	F1
holding	VERV	Common Stock						80,997	18 Mar 2022	Kathiresan Family 2021 Irrevocable Trust
holding	VERV	Common Stock						80,997	18 Mar 2022	Sekar Kathiresan 2021 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VERV	Stock Option (right to buy)	Options Exercise	$0	-69,674	-10%	$0.000000	605,308	18 Mar 2022	Common Stock	69,674	$2.87	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 1,315 shares of the Company's common stock acquired under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan.
F2	The remaining shares underlying this option, which was granted on September 16, 2020, vest in equal monthly installments until September 16, 2024.